Nordic Nanovector ASA

📍 Oslo, Norway🗓 Founded 2009👥 20 employees💰 Last funded 2011
Biotechnology Research🌐 nordicnanovector.com
Website LinkedIn
Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs. The Company aspires to become a leader in the development of CD37-targeted therapies for haematological cancers and immune diseases. Nordic Nanovector's lead clinical-stage candidate is Betalutin®, a novel CD37-targeting antibody-radionuclide-conjugate designed to advance the treatment of non-Hodgkin's lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 26 billion by 2028. Nordic Nanovector retains global marketing rights to Betalutin® and intends to actively participate in the commercialisation of Betalutin® in the US and other major markets.
1
Total investors
1
Early stage
0
Mid stage
0
Late stage
2009
Founded

Investors

1 investor
All
Early stage
Mid stage
Late stage
Investor geography1 country
Norway
1
Frequently asked questions
Who invested in Nordic Nanovector ASA?
Nordic Nanovector ASA has 1 investor on record on gritt.io, including 1 early-stage backers.
When did Nordic Nanovector ASA last raise funding?
The most recent investment in Nordic Nanovector ASA recorded on gritt.io was in 2011.
When was Nordic Nanovector ASA founded?
Nordic Nanovector ASA was founded in 2009.
What industry is Nordic Nanovector ASA in?
Nordic Nanovector ASA operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Nordic Nanovector ASA based?
Nordic Nanovector ASA is headquartered in Oslo, Norway.